Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MOLMite
- Development stage
- Unknown
- Lead developer
- Worgpharma
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
**MOLMite** is a molecular house dust mite allergen immunotherapy developed for respiratory allergic disease caused by sensitization to *Dermatophagoides pteronyssinus*. It contains purified major mite allergens Der p 1, Der p 2, and Der p 23 and is administered by subcutaneous injection to promote allergen-specific immune tolerance. The product is being evaluated in a randomized, placebo-controlled Phase II dose-ranging trial for moderate-to-severe allergic rhinitis or allergic rhinoconjunctivitis, with or without controlled allergic asthma.
- Brand names
- MOLMite
- Other names
- MOL Mite
02
Targets
Der p 1-specific immune receptors/antibodiesDer p 23-specific immune receptors/antibodies
Beyond the preview
Go deeper on MOLMite.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MOLMite.